Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress

Frontiers in Pharmacology

Volumn 3 JUL, Issue , 2012, Pages

  Costell, Melissa H ^a   Ancellin, Nicolas ^b   Bernard, Roberta E ^a   Zhao, Shu Fang ^a   Upson, John J ^a   Morgan, Lisa A ^a   Maniscalco, Kristeen ^a   Olzinski, Alan R ^a   Ballard, Victoria L T ^a   Herry, Kenny ^b   Grondin, Pascal ^b   Dodic, Nerina ^b   Mirguet, Olivier ^b   Bouillot, Anne ^b   Gellibert, Francoise ^b,c   Coatney, Robert W ^a   Lepore, John J ^a   Jucker, Beat M ^a   Jolivette, Larry J ^a   Willette, Robert N ^a   Schnackenberg, Christine G ^a   Behm, David J ^a   more..

^a GLAXOSMITHKLINE   (United States)

^b Glaxo Smith Kline   (France)

^c INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

BAY 60 4552; cGMP; GSK2181236A; SHR SP; Soluble guanylate cyclase; VASP

Indexed keywords

1 [6 [2 [[[3 METHYL 4' [(TRIFLUOROMETHYL)OXY] 4 BIPHENYLYL]METHYL]OXY]PHENYL] 2 PYRIDINYL] 5 (TRIFLUOROMETHYL) 1H PYRAZOLE 4 CARBOXYLIC ACID; BUPIVACAINE; CARBACHOL; GSK 2181236A; GUANYLATE CYCLASE ACTIVATOR; NELOCIGUAT; NITROPRUSSIDE SODIUM; PROCAINAMIDE; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ELECTROCARDIOGRAPHY; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART FUNCTION; HEART HEMODYNAMICS; HEART VENTRICLE HYPERTROPHY; KIDNEY FUNCTION; MALE; NONHUMAN; OXIDATIVE STRESS; PAIN; PROTEIN PHOSPHORYLATION; RAT; RENAL PROTECTION; REPERFUSION INJURY; SURVIVAL RATE; THORACOTOMY; VASODILATATION;

EID: 84866166276     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00128     Document Type: Article

References (36)

1. Barone, R C., Coatney, R. W., Chandrac, S., Sarkarc, S. K., Nelson, A. H., Contino, L. C., Brooks, D. P., Campbell, W. G., Ohlstein, E. H., and Willette, R. N. (2001). Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats. Cardiovasc. Res. 50, 525-537.
2. Bauersachs, J., and Widder, J. D. (2008). Endothelial dysfunction in heart failure. Pharmacol. Rep. 60, 119-126.
3. Behr, T. M., Nerurkar, S. S., Nelson, A. H., Coatney, R. W., Woods, T. N., Sulpizio, A., Chandra, S., Brooks, D. P., Kumar, S., Lee, J. C., Ohlstein, E. H., Angermann, C. E., Adams, J. L., Sisko, J., Sackner-Bernstein, J. D., and Willette, R. N. (2001). Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 104, 1292-1298.
4. Benz, K., Orth, S. R., Simonaviciene, A., Linz, W., Schindler, U., Rütten, H., and Amann, K. (2007). Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage. Kidney Blood Press. Res. 30, 224-233.
5. Bolli, R. (2001). Cardioprotective function of inducible nitric oxide syn-thase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J. Mol. Cell. Cardiol. 33, 1897-1918.
6. Brunton, T. (1867). On the use of nitrite of amyl in angina pectoris. Lancet 2, 97-98.
7. Burley, D. S., Ferdinandy, P., and Baxter, G. F. (2007). Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br. J. Pharmacol. 152, 855-869.
8. Choi, B. M., Pae, H. O., Jang, S. I., Kim, Y. M., and Chung, H. T. (2002). Nitric oxide as a pro-apoptotic as well as anti-apoptotic modulator. J. Biochem. Mol. Biol. 35, 116-126.
9. Cohen, M. V., Yang, X. M., Liu, Y., Solenkova, N. V., and Downey, J. M. (2010). Cardioprotective PKG-independent NO signaling at reper-fusion. Am. J. Physiol. Heart Circ. Physiol. 299, H2028-H2036.
10. Erdmann, E., Semigran, M. J., Niemi-nen, M. S., Agrawal, R., Mitrovic, V., andMebazaa, A. (2010). Cinaciguat, a soluble guanylate cyclase activator, unloads the heart in acute decom-pensated heart failure. J. Am. Coll. Cardiol. 55, A16.E147.
11. Evgenov, O. V., Pacher, P., Schmidt, P. M., Haskó, G., Schmidt, H. H., and Stasch, J. P. (2006). NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov. 5, 755-768.
12. Furchgott, R.F. (1988). "Studies on relaxation of rabbit aorta by sodium nitrate: the basis for the proposal that the acid-activatable inhibitory factor from bovine retractor penis is inorganic nitrate and the endothelium-derived relaxing factor is nitric oxide, " in Mechanism of Vasodilation, Vol. 4, ed. P. M. Vanhoutte (New York, NY: Raven Press), 401-414.
13. Jones, E. S., Kemp-Harper, B. K., Stasch, J., Schmidt, H. H. H. W., and Widdop, R. E. (2009). Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation/activation of sGC without hypotension. BMC Pharmacol. 9(Suppl. 1), 29. doi:10.1186/1471-2210-9-S1-P29
14. Ju, H., Behm, D. J., Nerurkar, S., Eybye, M. E., Haimbach, R. E., Olzinski, A. R., Douglas, S. A., and Willette, R. N. (2003). p38 MAPK inhibitors ameliorate target organ damage in hypertension: part 1. p38 MAPK-dependent endothelial dysfunction and hypertension. J. Pharmacol. Exp. Ther. 307, 932-938.
15. Kerr, S., Brosnan, M. J., McIntyre, M., Reid, J. L., Dominiczak, A. F., and Hamilton, C. A. (1999). Superox-ide anion production is increased in a model of genetic hypertension: the role of the endothelium. Hypertension 33, 1353-1358.
16. Ko, E N., Wu, C. C., Kuo, S. C., Lee, E Y., and Teng, C. M. (1994). YC-1, a novel activator of platelet guanylate cyclase. Blood 84, 4226-4233.
17. Korkmaz, S., Radovits, T., Barnucz, E., Hirschberg, K., Neugebauer, P., Loganathan, S., Veres, G., Páli, S., Seidel, B., Zöllner, S., Karck, M., and Szabó, G. (2009). Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury. Circulation 120, 677-686.
18. Krieg, T., Liu, Y., Rütz, T., Methner, C., Yang, X. M., Dost, T., Felix, S. B., Stasch, J. P., Cohen, M. V., and Downey, J. M. (2009). BAY 58-2667, a nitric oxide-independent guany-lyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. Eur. Heart J. 30, 1607-1613.
19. Lang, R. M., Bierig, M., Deveruex, R. B., Flachsklampf, E A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., Solomon, S. D., Spencer, K. T., St John-Sutton, M., and Stewart, W. J. (2005). Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Groups, developed in conjunction with the European Association of Echocardiography, abranch of the European Society of Echocardiog-raphy. J. Am. Soc. Echocardiogr. 18, 1440-1463.
20. Lindenfeld, J., Albert, N. M., Boehmer, J. P., Collins, S. P., Ezekowitz, J. A., Givertz, M. M., Klapholz, M., Moser, D. K., Rogers, J. G., Starling, R. C., Stevenson, W. G., Tang, W. H. W., Teerlink, J. R., and Walsh, M. N. (2010). HFSA 2010 comprehensive heart failure practice guideline. J. Card. Fail. 16, e1-e194.
21. Ma, X. L., Gao, F., Nelson, A. H., Lopez, B. L., Christopher, T. A., Yue, T. L., and Barone, E C. (2001). Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. J. Pharmacol. Exp. Ther. 298, 879-885.
22. McIntyre, M., Bohr, D. F., and Dominiczak, A. E (1999). Endothelial function in hypertension: the role of superoxide anion. Hypertension 34, 539-545.
23. McIntyre, M., Hamilton, C. A., Rees, D. D., and Reid, J. L, Dominiczak, A. E (1997). Sex differences in the abundance of endothelial nitric oxide in a model of genetic hypertension. Hypertension 30, 1517-1524.
24. Mitrovic, V., Jovanovic, A., and Lehi-nant, S. (2011). Soluble guanylate cyclase modulators in heart failure. Curr. Heart Fail. Rep. 8, 38-44.
25. Mitrovic, V., Swidnicki, B., Ghofrani, A., Mück, W., Kirschbaum, N., Mitten-dorf, J., Stasch, J. P., Wensing, G., Frey, R., andLentini, S. (2009). Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure. BMC Pharmacol. 9(Suppl. I), 51. doi:10.1186/1471-2210-9-S1-P51
26. Pacher, P., Beckman, J. S., and Liaudet, L. (2007). Nitric oxide and peroxyni-trite in health and disease. Physiol. Rev. 87, 315-424.
27. Palmer, R. M., Ferrige, A. G., and Moncada, S. (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327, 524-526.
28. Schindler, U., Strobel, H., Schönafin-ger, K., Linz, W., Löhn, M., Mar-torana, P. A., Rütten, H., Schindler, P. W., Busch, A. E., Sohn, M., Töpfer, A., Pistorius, A., Jannek, C., and Mülsch, A. (2006). Biochemistry and pharmacology of novel anthranilic acid derivatives activating hemeoxidized soluble guanylyl cyclase. Mol. Pharmacol. 69, 1260-1268.
29. Schulz, R., Kelm, M., and Heusch, G. (2004). Nitric oxide in myocardial ischemia/reperfusion injury. Cardio-vasc. Res. 61, 402-413.
30. Seddon, M., Looi, Y. H., and Shah, A. M. (2007). Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 93, 903-907.
31. Stamler, J. S., Simon, D. I., Osborne, J. A., Mullins, M. E., Jaraki, O., Michel, T., Singel, D. J., and Loscalzo, J. (1992). S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc. Natl. Acad. Sci. U.S.A. 89, 444-448.
32. Stasch, J. P., Dembowsky, K., Perzborn, E., Stahl, E., and Schramm, M. (2002a). Cardiovascular actions of a novel NO-independent guany-lyl cyclase stimulator, BAY 41-8543: in vivo studies. Br. J. Pharmacol. 135, 344-355.
33. Stasch, J. P., Schmidt, P., Alonso-Alija, C., Apeler, H., Dembowsky, K., Haerter, M., Heil, M., Minuth, T., Perzborn, E., Pleiss, U., Schramm, M., Schroeder, W., Schröder, H., Stahl, E., Steinke, W., and Wun-der, E. (2002b). NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br. J. Pharmacol. 136, 773-783.
34. Stasch, J. P., Schmidt, P. M., Nedvetsky, P. I., Nedvetskaya, T. Y., H S, A. K., Meurer, S., Deile, M., Taye, A., Knorr, A., Lapp, H., Müller, H., Turgay, Y., Rothkegel, C., Tersteegen, A., Kemp-Harper, B., Müller-Esterl, W., and Schmidt, H.H. (2006). Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J. Clin. Invest. 116, 2552-2561.
35. Willette, R. N., Eybye, M. E., Olzin-ski, A. R., Behm, D. J., Aiyar, N., Maniscalco, K., Bentley, R. G., Coat-ney, R. W., Zhao, S., Westfall, T. D., and Doe, C. P. (2009). Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J. Pharmacol. Exp. Ther. 330, 964-970.
36. Zhou, Z., Pyriochou, A., Kotanidou, A., Dalkas, G., van Eickels, M., Spyroulias, G., Roussos, C., and Papapetropoulos, A. (2008). Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 295, H1763-H1771.